Novo Nordisk A/S Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 4, 2026 results vs estimates
Novo Nordisk A/S Forecast
Novo Nordisk A/S short-term momentum is neutral (up over 2 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term NEUTRAL signal. The long-term trend is negative (2 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 20.7% a year, a typical one-standard-deviation range is 38.00–40.28 over a week, 36.80–41.48 over a month and 31.03–47.25 over a year. (Signals as of 1 Nov 2026.)
Novo Nordisk A/S Price Chart
Novo Nordisk A/S Factors
YoY −25.2%
YoY −22.8%
YoY −36.3%
YoY −15.8%
YoY −12.9%
YoY −6.9%
YoY +33.6%
YoY −33.8%
YoY −18.4%
YoY +24.3%
YoY +13.7%
YoY +8.9%
YoY +11.6%
YoY +40.5%
YoY +3.6%
YoY +25.0%
YoY −7.7%
Novo Nordisk A/S fundamentals: income statement, balance sheet & cash flow
Novo Nordisk A/S reported revenue of $309.06bn and net income of $102.43bn in FY2025, the year ended 31 December 2025 — revenue up 6.4% and net income up 1.4% on the prior year. Free cash flow was $28.99bn. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD billions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 309.06 | 290.40 | 232.26 | 176.95 | 140.80 |
| Cost of revenue | 58.79 | 44.52 | 35.77 | 28.45 | 23.66 |
| Gross profit | 250.28 | 245.88 | 196.50 | 148.51 | 117.14 |
| Research & development | 52.04 | 48.06 | 32.44 | 24.05 | 17.77 |
| Selling, general & admin. | 70.58 | 69.48 | 61.48 | 49.65 | 40.73 |
| Operating income | 127.66 | 128.34 | 102.57 | 74.81 | 58.64 |
| EBITDA | 156.73 | 147.94 | 114.63 | 76.80 | 65.39 |
| Interest expense | 4.21 | 1.64 | 0.54 | 0.38 | 0.29 |
| Pre-tax income | 130.54 | 127.19 | 104.67 | 69.06 | 59.08 |
| Income tax | 28.11 | 26.20 | 20.99 | 13.54 | 11.32 |
| Net income | 102.43 | 100.99 | 83.68 | 55.53 | 47.76 |
Download Novo Nordisk A/S fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.NVO.NYSE&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Novo Nordisk A/S
Explore MacroFinance macro & markets research and analysis.
Novo Nordisk A/S Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Novo Nordisk A/S; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Novo Nordisk A/S’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Novo Nordisk A/S (United States)
Novo Nordisk A/S is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Novo Nordisk A/S
Frequently asked questions
What is Novo Nordisk A/S?
What is the latest Novo Nordisk A/S price?
Is Novo Nordisk A/S in an uptrend?
How volatile is Novo Nordisk A/S?
What factors affect Novo Nordisk A/S?
Which trading strategies trade Novo Nordisk A/S?
How are Novo Nordisk A/S returns analysed?
Where can I download free Novo Nordisk A/S historical data?
Free Novo Nordisk A/S historical data (last 10 years)
Browse or instantly download the last 10 years of Novo Nordisk A/S daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.NVO.NYSE&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 37.82 |
| 2026-11-19 | 38.87 |
| 2026-11-18 | 39.43 |
| 2026-11-17 | 40.7 |
| 2026-11-16 | 41.6 |
| 2026-11-13 | 41.63 |
| 2026-11-12 | 40.65 |
| 2026-11-11 | 41.09 |
| 2026-11-10 | 40.7 |
| 2026-11-09 | 41.38 |
About this stock
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.